OBX-115，its Engineered TIL Cell Therapy，for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting

• 原始preliminary results from Phase1study of OBX-115，novel engineered tumor-derived autologous T cell immunotherapy（tumor-infiltrating lymphocyte[TIL]cell therapy）armored with pharmacologicallly regulatable membrane-bound IL15（mbIL15），内插式导流器或metastatic melanoma
• Additional trial-in progress poster presentation outlining the details of the ongoing Phase1/2 trial of OBX-115 in patients with advanced solid tumors

CAMBRIDGE，Mass.--（BUSINESS WIRE）--Obsidian Therapeutics，Inc。，a clinical-stage biotechnology company pioneering engineered cell and gene therapies，today announced two presentations，including an oral presentation on the Phase1 first-in-human study of OBX-115，a novel engineered tumor-derived autologous T cell immunotherapycell therapy armored with pharmacologicallly regulatable membrane-bound IL15（mbIL15），in patients with immune checkpoint inhibitor（ICI）-resistant advanced or metatic melanoma（NCT 05470283），at the 2024 American Society of Clinical Oncology（ASCO）Annual Meeting，taking place in Chicago on May31–June 4。

原始位置准备

• 标题：OBX-115，an interleukin2（IL2）-sparing engineered tumor-infiltrating lymphocyte（TIL）cell therapy，in patients（pts）with immune checkpoint inhibitor（ICI）-resistant unresectable or metatic melanoma。
• Session Title:Rapid Oral Abstract–Melanoma/Skin Cancers
• 日期和时间：Monday，June3，at9:45a.m.CT/10:45a.m.ET
• Abstract Number:9515
• Speaker/Lead Author:Rodabe N Amaria，M.D.，The University of Texas MD Anderson Cancer Center
• Clinical Trial Identifier：NCT 05470283（First-in-human study）

列车在进度前方准备

• 标题：A phase1/2study to investigate the safety and efficacy of OBX-115engineered tumor-infiltrating lymphocyte（TIL）cell therapy in patients（pts）with advanced solid tumors。
• Session Title:Poster Session–Melanoma/Skin Cancers
• 日期和时间：Saturday，June1，at1:30p.m.CT/2:30p.m.ET
• Abstract Number:TPS9599
• Speaker/Lead Author:Adam J Schoenfeld，M.D.，Memorial Sloan Kettering Cancer Center
• Clinical Trial Identifier：NCT060613多个对象

About OBX-115

Obsidian’slead investigational cytoTIL15™program，OBX-115，is anovered tumor-derived autologous T cell immunotherapy（tumor-infiltrating lymphocyte[TIL]cell therapy）armored with pharmacologicallly regulatable membrane-bound IL15（mbIL15）。OBX-115has the potential to become a meaningful therapeutic option for patients with advanced or metatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15and Obsidian’s proprietary，differentiated manufacturing process to enhance persistence，antitumor activity，and clinical safety of TIL cell therapy.OBX-115is being investigated in two ongoing and enrolling clinical trials in advanced or metastatic melanoma and NSCLC（NCT 05470283and，andNCT060613）。

About Obsidian Therapeutics

Obsidian Therapeutics，Inc.is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.Obsidian’s proprietary cytoDRiVE^®technology is designed to precisely regulate the timing and level of protein function byusing FDA-approved small-molecule drugs.Obsidian is headquartered in Cambridge，MA.The Company has collaborations with Bristol Myers Squibband Vertex Pharmaceuticals.For more information，please visitwww.obsidiantx.comand follow us on LinkedIn。

查看source version on businesswire.com：https://www.businesswire.com/news/home/20240424758976/en/